Atish Choudhury, MD PhD (@AtishChoudhury) profile picture

Atish Choudhury, MD PhD

@AtishChoudhury

Medical Oncologist Lank Center for Genitourinary Oncology @DanaFarber Views expressed herein are my own

 Boston, MA
scholar.google.com/citations?hl=en&user=sJ4jYT0AAAAJ
Joined September 2016
  • Tweets343
  • Following231
  • Followers1.2K
23Media
Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)Photo by Atish Choudhury, MD PhD (@AtishChoudhury)
Earlier is not automatically better. @AtishChoudhury MD, PhD, considers the right timing for radiopharmaceuticals in metastatic prostate cancer. Explore the debates at hubs.ly/Q04xcr8v0 #OLNGreatDebates
1
89
Atish Choudhury, MD PhD retweeted
Adam B. Weiner, MD (@Adam_Weiner535) profile picture
Adam B. Weiner, MD
@Adam_Weiner535Jul 9
🚨 ARTO long-term update in oligometastatic mCRPC: SBRT to all mets + abi/ADT vs abi/ADT alone. @TheLancetOncol 👥 157 pts 🎯 ≤3 bone/nodal mets 💊 Abiraterone + ADT ± MDT/SBRT ⏱️ Median follow-up: 53 mo Results: ✅ OS: NR vs 50 mo ✅ HR 0.55, p=0.021 ✅ bPFS: 44 vs 18 mo ✅ rPFS: 44 vs 17 mo ✅ PC-specific survival improved ✅ No major toxicity signal from adding SBRT Big signal: MDT may be more than “delay next therapy” in oligometastatic CRPC. Caveat: phase 2, unplanned OS analysis, not originally powered for OS. Still: hard to ignore. 🔥 🔗shorturl.at/rEx5L @PCFnews @PCF_Science @urotoday @renalandurology @UrologyTimes #prostatecancer
Image from Adam B. Weiner, MD (@Adam_Weiner535)
Image from Adam B. Weiner, MD (@Adam_Weiner535)
Image from Adam B. Weiner, MD (@Adam_Weiner535)
2
21
39
3,059
Interesting study demonstrating equivalent long-term outcomes with treatment continuation vs interruption in exceptional responders to PARPi in PS-ROC. May support strategy of PARPi interruption in exceptional responders in met PrCa as well. jamanetwork.com/journals/jam…
Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors

This cohort study explores the long-term outcomes of patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to poly(adenosine diphosphate-ribose) polymerase (PARP)...

jamanetwork.com
1
1
4
303
Atish Choudhury, MD PhD retweeted
GU Oncology Now (@GUOncologyNow) profile picture
GU Oncology Now@GUOncologyNowJul 2
📈 In this interview, @AtishChoudhury, of @DanaFarber, discusses the key findings from the A-DREAM trial thatevaluated ADT interruption in patients with metastatic hormone-sensitive #prostatecancer who responded well to an androgen receptor pathway inhibitor: buff.ly/X39QmSz
4
8
738
Atish Choudhury, MD PhD retweeted
Zach Klaassen (@zklaassen_md) profile picture
Zach Klaassen
@zklaassen_mdJun 1
DE-ESCALATE (@EORTC): A pragmatic trial to revisit intermittent ADT in mHSPC in the era of new ARPIs @urotoday #ASCO26 🌟n=1,600 🌟Key elig criteria: mHSPC pts, PSA ≤ 0.2 at 6-12 mos after Rx start 🌟2:1 randomization to cMAB vs iMAB 🌟Co-primary EPs: (i) feasibility (ii) overall survival 🌟Status: May 1, 2026: 211 pts enrolled
Image from Zach Klaassen (@zklaassen_md)
12
17
736
Atish Choudhury, MD PhD retweeted
Dana-Farber News (@DanaFarberNews) profile picture
Dana-Farber News
@DanaFarberNewsMay 31
DREAM/Alliance A032101 presented by @DanaFarber's Dr. Atish Choudhury (@AtishChoudhury) at #ASCO26 shows 41% of favorable responders to testosterone suppression + ARPI remaining treatment-free w/testosterone recovery at 18 months after treatment interruption. CC: @DanaFarber_GU
2
9
28
2,729
Atish Choudhury, MD PhD retweeted
Zach Klaassen (@zklaassen_md) profile picture
Zach Klaassen
@zklaassen_mdMay 31
CLEARED: Comeback from long course ADT with relugolix and daro in hormone-sensitive PCa @AtishChoudhury @urotoday #ASCO26 🌟Rel + Daro: safe, well-tolerated during first 6 cycles -- PK parameters similar to historical mono Rel 🌟Pts will be followed after end of Rx for 1 EP of T recovery
Image from Zach Klaassen (@zklaassen_md)
Image from Zach Klaassen (@zklaassen_md)
Image from Zach Klaassen (@zklaassen_md)
Image from Zach Klaassen (@zklaassen_md)
9
12
565
Two Alliance oral abstract presentations today at #ASCO26 spotlight efforts to optimize treatment for men with advanced #prostatecancer. @AtishChoudhury presents A-DREAM (A032101) and @CAPsurvivorship presents ARACOG (AFT-47) #NCI #NCTN #GUOnc #CancerResearch @DanaFarber
Image from Alliance for Clinical Trials in Oncology (@ALLIANCE_org)
4
8
381
So proud of our Gelb Center for Translational Research manager Jasmine Lee for her poster summarizing our experience with on-treatment PSMA PET/CT in patients receiving ADT+ARPI for mHSPC, with a majority eventually being able to take a treatment break. @DanaFarber_GU
Image from Atish Choudhury, MD PhD (@AtishChoudhury)
4
4
1
17
971
Of the 19 patients with negative PET, 16 interrupted treatment, of whom only 3 resumed to date. Of the 36 patients with previously untreated PSMA avid disease, 11 received RT to residual disease, and 18 interrupted treatment of whom only 6 resumed to date.
1
3
1,245
Atish Choudhury, MD PhD retweeted
Dana-Farber News (@DanaFarberNews) profile picture
Dana-Farber News
@DanaFarberNewsFeb 26
At #ASCOGU26: @AtishChoudhury details research that addresses what happens with PSMA PET/CT imaging for patients who present with metastatic prostate cancer and start hormone treatments. @DanaFarber_GU @DanaFarber
2
7
825
How early is too early for lutetium PSMA in metastatic prostate cancer? The data is evolving and comfort with the therapy is growing, but sequencing remains unsettled. Should lutetium PSMA move forward in mCRPC while patients are fitter and disease burden may be lower? Or is its impact strongest when reserved for later lines, after AR targeted therapy and chemotherapy? At #OLNGreatDebates, @kai_tsao, MD, MS, and @AtishChoudhury MD, PhD take opposing positions on when this therapy truly delivers the most value. Hear both sides. Then decide where you stand. Join us: hubs.ly/Q044VHJH0 #ProstateCancer #GUOncology #mCRPC
Image from OLN Great Debates in Solid Tumors (@OLNGreatDebates)
2
1
170
Thank you for the kind invitation to give this talk to such an esteemed group! I appreciate the warm reception from @DoctorSotelo, Leo Doumanian, Inderbill Gill and the rest of the team, and I found the sessions to be very enlightening.
USC Urology (@USC_Urology) profile pictureUSC Urology
@USC_UrologyJan 31
Dr. Atish Choudhury joins us to discuss novel treatments for advanced prostate cancer. #practicalurology26
Image from USC Urology (@USC_Urology)
1
2
1
12
5,017
Atish Choudhury, MD PhD retweeted
The ASCO Post (@ASCOPost) profile picture
The ASCO Post@ASCOPost14 Dec 2025
Dr. @AtishChoudhury reviews oral relugolix vs injectable leuprolide for androgen deprivation therapy in #ProstateCancer, including HERO trial outcomes and new insights on cardiovascular risk with oral therapy. 🎦Watch the video: ascopost.com/videos/thematic…
Image from The ASCO Post (@ASCOPost)
1
1
5
1,075
Atish Choudhury, MD PhD retweeted
Russell Pachynski (@RPachynski) profile picture
Russell Pachynski@RPachynski7 Dec 2025
Don't know how Sipuleucel-T (Provenge) works - or how we can make it better? 🤔 Check out our hot-off-the-press review in @jitcancer 🔥 Sip-T was the FIRST approved cellular vaccine therapy for ANY cancer (2010)! jitc.bmj.com/content/13/12/e…
Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resist...

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resist...

Clinical trials of immunotherapy in metastatic castration-resistant prostate cancer (mCRPC) have largely been unsuccessful despite promising preclinical studies and proven efficacy in other solid...

jitc.bmj.com
1
2
3
9
1,392
Congratulations to @autumngagnonn on her publication demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping. @DanaFarber_GU secure-web.cisco.com/1Hbfbiu…
1
3
10
1,182
It's that time of year again! Please consider joining BellissiMo at movember.com/t/bellissimo?mc… to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources. Thank you @Movember for highlighting my journey. us.movember.com/story/from-r…

BellissiMo's Mo Space

Movember, the month formerly known as November, is a moustache growing charity event held during November each year that raises funds and awareness for men's health.

us.movember.com
7
244
Atish Choudhury, MD PhD retweeted
Neeraj Agarwal, MD, FASCO (@neerajaiims) profile picture
Neeraj Agarwal, MD, FASCO
@neerajaiims28 Oct 2025
Just in @TheLancetOncol 👉Ph3 CYCLONE 2: Abemaciclib + abiraterone vs. abi did not improve rPFS (primary endpoint) in mCRPC #ProstateCancer. Higher-risk pts (M1 at dx, Gleason ≥8, ⬆️PSA) seem to benefit more @OncoAlert @urotoday @PCF_Science Link👉 bit.ly/43HvEZJ
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
Image from Neeraj Agarwal, MD, FASCO (@neerajaiims)
1
37
2
84
10,085
Atish Choudhury, MD PhD retweeted
UroToday.com (@urotoday) profile picture
UroToday.com
@urotoday22 Sep 2025
Tazemetostat + talazoparib for metastatic castration-resistant #ProstateCancer. @AtishChoudhury @DanaFarber joins Evan Yu, MD @fredhutch to discuss a first-in-human trial combining EZH2 and PARP inhibition in #mCRPC. #WatchNow on UroToday > bit.ly/4oVI9tJ
Image from UroToday.com (@urotoday)
2
4
941
Truly a joy to participate in @TheJimmyFund Radio-Telethon with Kevin! audacy.com/podcast/weei-afte…
Image from Atish Choudhury, MD PhD (@AtishChoudhury)
Atish Choudhury, MD PhD (@AtishChoudhury) profile pictureAtish Choudhury, MD PhD@AtishChoudhury21 Aug 2025
I am so appreciative that my dear patient Kevin was willing to come out to Fenway Park for the @WEEI / @NESN @TheJimmyFund Radio-Telethon to raise awareness around prostate cancer and to support research at @DanaFarber @DanaFarber_GU. #KCANCER audacy.com/podcast/weei-afte…
2
7
425
Load more